CD44 MEDIATED FIBROBLAST MIGRATION IN A WOUND MODEL

本项目的主要目标是通过以下方式审查这些机制： CD 44细胞表面受体介导人真皮成纤维细胞 迁移到临时纤维蛋白基质中。伤口愈合是一个很好的 有组织的级联事件，涉及各种 细胞类型、生长因子和细胞外基质蛋白。 在 除了提供止血和保护外， 在创伤后立即形成的细胞充当成纤维细胞在其上生长的网格， 迁移以开始修复过程。 人牙槽骨的研究 来自急性肺损伤患者的成纤维细胞涉及 CD 44细胞表面受体在侵袭临时基质中的作用。 CD44 是一个涉及淋巴细胞归巢的细胞表面受体家族 以及肿瘤细胞迁移和转移。 整合素细胞 表面受体与人皮肤成纤维细胞有关 临时伤口基质的侵袭;然而，CD 44在 真皮成纤维细胞迁移的机制尚不清楚。 这项建议 将测试CD 44是人类真皮层细胞增殖的介质的假设。 成纤维细胞迁移到临时伤口基质中。 这项研究将 检查：1. CD 44介导的真皮成纤维细胞与各种 临时基质组分; 2. CD 44介导的真皮成纤维细胞 沿着临时基质组分迁移;和3. CD 44介导 纤维蛋白凝胶的真皮成纤维细胞侵入。 了解 成纤维细胞迁移的机制将为 开发治疗纤维化病症的新疗法。

The primary objective of this project is to examine the mechanisms by which the CD44 cell surface receptor mediates human dermal fibroblast migration into the provisional fibrin matrix. Wound healing is a finely organized cascade of events involving the interactions of a variety of cell types, growth factors, and extracellular matrix proteins. In addition to providing hemostasis and protection, the fibrin plug which forms immediately upon wounding serves as a lattice on which fibroblasts migrate to begin the healing process. Studies of human alveolar fibroblasts derived from patients with acute lung injury implicate the CD44 cell surface receptor in invasion of the provisional matrix. CD44 is a family of cell surface receptors implicated in lymphocyte homing as well as tumor cell migration and metastasis. The integrin cell surface receptors have been implicated in human dermal fibroblast invasion of the provisional wound matrix; however, the role of CD44 in the mechanism of dermal fibroblast migration is unknown. This proposal will test the hypothesis that CD44 is a mediator of human dermal fibroblast migration into the provisional wound matrix. The study will examine: 1. CD44-mediated dermal fibroblast adhesion to various provisional matrix components; 2. CD44-mediated dermal fibroblast migration along provisional matrix components; and 3. CD44-mediated dermal fibroblast invasion of a fibrin gel. Understanding the mechanisms of fibroblast migration will provide a basis for the development of novel therapies in the treatment of fibrotic disorders.